165 related articles for article (PubMed ID: 38050039)
1. Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate.
Ladror D; Gu C; Tong V; Schammel A; Gavrilyuk J; Haight A; Sarvaiya H
Drug Metab Dispos; 2024 Jan; 52(2):135-142. PubMed ID: 38050039
[TBL] [Abstract][Full Text] [Related]
2. Calicheamicin Antibody-Drug Conjugates with Improved Properties.
Vollmar BS; Frantz C; Schutten MM; Zhong F; Del Rosario G; Go MAT; Yu SF; Leipold DD; Kamath AV; Ng C; Xu K; Dela Cruz-Chuh J; Kozak KR; Chen J; Xu Z; Wai J; Adhikari P; Erickson HK; Dragovich PS; Polson AG; Pillow TH
Mol Cancer Ther; 2021 Jun; 20(6):1112-1120. PubMed ID: 33722856
[TBL] [Abstract][Full Text] [Related]
3. ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors.
Wiedemeyer WR; Gavrilyuk J; Schammel A; Zhao X; Sarvaiya H; Pysz M; Gu C; You M; Isse K; Sullivan T; French D; Lee C; Dang AT; Zhang Z; Aujay M; Bankovich AJ; Vitorino P
Mol Cancer Ther; 2022 Jun; 21(6):986-998. PubMed ID: 35642431
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
5. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
Ma H; Sawas A
Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Opportunities to Develop Enediyne Natural Products as Payloads for Antibody-Drug Conjugates.
Adhikari A; Shen B; Rader C
Antib Ther; 2021 Jan; 4(1):1-15. PubMed ID: 33554043
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
9. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates in Myeloid Leukemias.
Senapati J; Daver NG; Pemmaraju N
Cancer J; 2022 Nov-Dec 01; 28(6):454-461. PubMed ID: 36383908
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia.
Stokke JL; Bhojwani D
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441852
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
Hibma J; Knight B
Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aujla A; Aujla R; Liu D
Biomark Res; 2019; 7():9. PubMed ID: 31011424
[TBL] [Abstract][Full Text] [Related]
15. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
16. The clinical development of antibody-drug conjugates - lessons from leukaemia.
Jabbour E; Paul S; Kantarjian H
Nat Rev Clin Oncol; 2021 Jul; 18(7):418-433. PubMed ID: 33758376
[TBL] [Abstract][Full Text] [Related]
17. Total Synthesis in Search of Potent Antibody-Drug Conjugate Payloads. From the Fundamentals to the Translational.
Nicolaou KC; Rigol S
Acc Chem Res; 2019 Jan; 52(1):127-139. PubMed ID: 30575399
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugate technology development for hematologic disorders.
Bander NH; Czuczman MS; Younes A
Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
[TBL] [Abstract][Full Text] [Related]
19. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
